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Abstract Peroxiredoxins (Prxs) constitute a novel family of antioxidant proteins, which specifically prevent enzymes
frommetal-catalyzed oxidation.The localization of a member of the mono-cystein subfamily of Prxs, Prx VI in human
respiratory systemandits antioxidantpropertieswere investigated.Byimmunoblotting, the PrxVIwas found to bepre-
sent inhumanrespiratoryepithelium.Immunostainingwithrabbit polyclonal antibodyraised againstthe PrxVIrevealed
thatthe saidproteinwaspresent in apical areas andmucus of allrespiratory airways fromtrachea to bronchioles. Immu-
nodepletion of the Prx VI profoundly decreased the antioxidant activity of the respiratory epithelium extract. r 2002
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Respiratory system due to peculiarities of its texture,
structure and functions has increased capability for reac-
tive oxygen intermediates (ROI) formation and for con-
secutive free radicals reaction as lungs are exposed to
both endogenous and inhaled free radicals.The oxidative
burden of a healthy lung is balanced by the local antioxi-
dant defenses (1). Since hydrogen peroxide (H2O2) is a
precursor of highly reactive hydroxyl radical (OH?), lung
antioxidant strategy is based inmany respects on perox-
ide inactivation system, that includes several enzymes, of
which catalase and glutation-redox cycle enzymes are
basic ones. In addition to well-documented antioxidant
enzymes, a novel family of antioxidant enzymes, desig-
nated peroxiredoxins (Prxs), has recently been discov-
ered in both eucaryote and procaryote cells. Prx family
members in the presence of some thiols can speci¢cally
preventbiopolymers (proteins, nucleic acids, lipids) from
damage by reactive oxygen species (2). Mammalian Prxs
are classi¢ed into sixdistinctgroups,Prx I^PrxVI, based
on amino acid sequences and immunological reactivity
(3,4). Prx VI was detected in olfactory and respiratory
epithelium of rats (EMBL/GenBank, accession number
Y17295) (5^7). Based on electron microscopy immuno-
histochemistry data authors suppose that respiratoryReceived 28 July 2001, accepted in revised form17 July 2002
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£uid, thus Prx VI is a secretory protein (8). It is
generally known that ELF constitutes the ¢rst andmost
likely basic line lung antioxidant defense (1). A compari-
son of rats Prx VI sequences with protein sequences in
EMBL and GenBank databases revealed human protein
(ORF6) with 91% similarity (GenBank, D14662). The aim
of this study is elucidation of Prx VI expression pattern
and contribution to antioxidant defense of human re-
spiratory airways.
PREPARATIONOFWATER-SOLUBLE
EXTRACTOF TRACHEA
Trachea specimens for immunohistochemistry and bio-
chemical analysis were derived from six men at autopsy
within 10h after decrease. Autopsy showed absence of
any abnormalities in lungs.
Lung biopsy specimens for immunohistochemistry
from four subjects with normal histopathology under-
going surgery for lung cancer were retrieved from the
¢les of the Department of Pathology, Pulmonology Re-
search Institute,Moscow.
Isolated tissue from human trachea was homogenized
in 10mM sodium phosphate bu¡er containing 150mM
NaCl and 0.5mM phenylmethylsulfonyl £uoride
(PMSF), pH 7.4. The homogenate was centrifuged at
20 000g for 1h, and the supernatant (total protein con-
centration approximately1mg/ml)was used aswater-so-
luble extract.
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POLYCLONALANTIBODYAGAINST
RECOMBINANTHUMAN
PEROXIREDOXINVI, AND
IMMUNOBLOTTING
Rabbit polyclonal antibody against the recombinant hu-
man Prx VI was produced as previously described (8).
The protein (300mg of antigen per immunization) was
emulsi¢ed with complete Freund’s adjuvant for the ¢rst
immunization, then by boost in incomplete Freund’s ad-
juvant at 3 weeks. The antiserum was diluted 1:200 for
lightmicroscopy.
SDS-polyacrylamide gel electrophoresis (PAGE) was
performed under reducing condition on 10% slab gels in
discontinuous bu¡er system, according to Laemmli (9).
Approximately 20 mg of total water-soluble protein was
used for SDS-PAGE gel lane.
Immunoblotting was performed as previously de-
scribed (8)
Protein concentrations were measured according to
the method of Bradford (1970), using serum albumin as
standard (10).
LIGHT-MICROSCOPIC
IMMUNOHISTOCHEMISTRY
Para⁄n sections 4^5mm thick were cut on microtome
and mounted on gelatin-coated microscope slides. The
sections were depara⁄nized in xylene and rehydrated
though a series of graded alcohols from absolute to
water. Sections were treatedwith 0.3% hydrogen perox-
ide for 5min to inactivate the endogennous peroxidase
activity and blocked for 30min with 2% bovine fetal ser-
um in10mM phosphate-bu¡ered saline, pH 7.5. Sections
werewashedwith10mM phosphate-bu¡ered saline, pH
7.5, and incubated with a primary rabbit antiserum
against PrxVI at a dilution1:200 for1h. Antibody binding
was detected using horseradish peroxidase-coupled
goat anti-rabbit secondary antibody. The complex was
visualized in10mM sodiumphosphate bu¡er, pH 7.5, con-
taining 0.15mM NaCl, 0.5mg/ml 30, 3-diaminobenzidine
tetrahydrochloride, and 0.015% hydrogen peroxide. To
evaluate nonspeci¢c staining, controls were incubated
with preimmune serum. The stained sections were ex-
amined under a camera-equipped Zeiss microscope. All
procedures were carried out at room temperature.
IMMUNODEPLETION
Anti-Prx VI IgGwas coupled to CNBr-activated sephar-
ose (Pharmacia, Sweden) according to the manufac-
turer’s instructions. For immunodepletion of the Prx VI,
10ml of water-soluble extract of human trachea contain-ing10mgof totalwater-solubleproteinwaspassed twice
through an antibody-a⁄nity column (0.53 cm)2. The
degree of the PrxVI immunodepletion in the trachea ex-
tract was evaluatedby immunoblotting.
INACTIVATIONOFGLUTAMINE
SYNTHETASEBY THEFE3+/
DITHIOTHREITOL/O2 SYSTEM
Escherichia coli glutamine synthetase was inactivated by
the Fe3+/dithiothreitol/O2 system as described pre-
viously (11). The inactivation reaction was performed in
60-ml reaction mixture containing 5mg of glutamine
synthetase, 3mM dithiothreitol (DTT), 3mMFeCl3, and
50mMHEPES bu¡er, pH 7.3. Protein sample (20ml of un-
treated or depleted extract of trachea) was also added.
After incubation at 251C for10min, the remaining activ-
ity of glutamine synthetase was measured as described
(11).
RESULTS
By immunoblotting, using rabbit polyclonal antibody
raised against the human recombinant Prx VI, we
showed here that Prx VI was present in water-soluble
extractof human trachea (Fig.1). In the casewhen antibo-
dies against rat 28-kDa peroxiredoxinwere used for im-
munoblotting, a similar picture was revealed (¢gure
missing).Thus Prx VI was identi¢ed in human trachea.
Weperformed light-microscopic immunohistochemis-
try examinationwith the purpose of clarifying Prx VI lo-
calization inhuman trachea and lungs.Themost intensive
immunostaining in trachea was observed in the apical
area andmucus (Fig. 2).
The immunoreactivity in lungwas observed inbronchi
and bronchioles of all generations including terminal
bronchioles in a pattern similar to that in the trachea
(Fig. 3). No immunoreactivity was apparent in other
areas of lung, such as alveolus and lung blood vessels.
To elucidate the role of the Prx VI in the endogenous
antioxidant system, we tested the e¡ect of immunode-
pletion of the Prx VI on the antioxidant property of the
trachea extract. For this study, we used the human tra-
chea epithelium depleted for Prx VI. For immunodeple-
tion, we used chromatography of the extract of the
trachea epithelium on anti-Prx VI antibody-a⁄nity col-
umn, and monitored the e⁄ciency of the Prx VI deple-
tion by immunoblotting. As shown in Fig. 4, two-step
chromatography completely removed the Prx VI from
the trachea tissue extract.
For testing the ability of the antioxidant inherent in
trachea tissue extract to prevent damages caused by
AOS, we used Fe+3/DTT/O2 system as its components
serve as electrondonors for Prxs andcan simultaneously
generate free radicals. As a component sensitive to
oxidation by Fe+3/DTT/O2 system, we employed gluta-
mine synthetase, the enzyme commonly used for inves-
tigating the properties of the antioxidants.
FIG. 1. Immunoblotoftracheaextract: lane1Fstainingwithcoo-
massieblue R-250; lane 2Fstainingwith antibodyagainst PrxVI.
FIG. 2. Localization of peroxiredoxinVI in human trachea. (a) Imm
oxiredoxinVI antiserum.Immunoreactivitywas visualizedusingpero
toxyline-and-eosin staining.The immunoreactivityis concentrated in
PEROXIREDOXINVIINHUMANRESPIRATORYSYSTEM 149As shown in Fig. 5, under the given experimental con-
ditions the levels of the antioxidant activity depleted ex-
tracts were not su⁄cient to protect glutamine
synthetase from inhibition by Fe+3/DTT/O2 system.The
low antioxidant activity exertedby the depleted isotonic
extracts can be attributed to catalase, which has pre-
viously been shown to protect glutamine synthetase
from inactivationby Fe+3/ascorbate/O2 system in the ab-
sence of any electron^ donor compounds (12).
As shown in Fig. 5, the protein concentration of the
untreated extract required for the 50% glutamine
synthetase protection was approximately 0.2mg/ml,
while depleted extract even with concentration of
1mg\ml provided only15% of glutamine synthetase pro-
tection. Calculated Prx VI contribution in total antioxi-
dant activity of human airways epithelium comes about
70%.
DISCUSSION
Currently, virtually all of the known antioxidants were
revealed in ELF (13). However, it should be stressed that
themain body of this results was obtained from bronch-
oalveolar lavage (BAL) studies. BAL studies do not allow
to detect the site of antioxidant enzymes synthesis and
the capacity of cells to secrete such protein actively. At
present, a rather limited number of immunohistochem-
istry data on cellular localization of antioxidants exists.
However, lung cellular residence of themostwidely in-
vestigatedhydrogenperoxide scavengingmechanisms in-
cluding catalase and extracellular glutathione peroxidase
(eGPx) are well known now.Themost intensive catalase
immunostaining was seen in type II pneumocytes, a les-
ser degree immunopositivity for catalase was detected
in bronchial epithelium and alveolar macrophages (14).
The human airway epithelium and alveolar macrophages
express and secrete eGPx into the apical surface lining
£uid (15).unohistochemical staining of the peroxiredoxinVIwith anti-per-
xidasereactionwith diaminobenzidine as a substrate. (b) Haema-
mucus and some epithelial cells.Bars 50 mm.
FIG. 3. Localization of peroxiredoxinVI in human lung. (a) Immunohistochemical staining of the peroxiredoxinVIwith anti-peroxire-
doxinVI antiserum.Immunoreactivity was visualizedusing peroxidase reactionwith diaminobenzidine as a substrate. (b) Haematoxy-
line-and-eosin staining.The immunoreactivity is concentrated inmucus and some epithelial cells.Bars 50 mm.
FIG. 4. Immunodepletion of the Prx VI in water-soluble ex-
tractofrespiratoryepithelium.Immunoblotofuntreatedextract
(lane1), immunoblotof depleted extract (lane 2).
FIG. 5. Protection of glutamine synthetase by water-soluble
extract of respiratory epithelium against the Fe3+ dithiothrei-
tol/O2.Balck circles represents untreated extract, white circles
immunodepleted extract.
150 RESPIRATORYMEDICINEGreat attentionhas latelybeenpaid to PrxsF a novel
family of antioxidants, though only a few studies of Prxs
in the ¢eld of respiratorymedicine have so far been pub-
lished. Kinnula and co-authors (16) reported that the
bronchial epithelium showed moderate-to-high expres-sion of Prxs, I, III, V and VI. The alveolar epithelium ex-
pressed mainly Prxs V and VI, alveolar macrophages
expressed Prxs I, III,V, and VI. In this study, the immunor-
eactivity for Prx,VI was observed in apical area of tra-
chea and bronchi, including bronchioles. No
immunoreactivity was apparent in other areas of lung,
such as alveolus and lungblood vessels in all biopsy speci-
mens.
These ¢ndings correspond with the facts obtained
from studies on rat which showed on immunopositivity
for Prx VI in alveolar area (8). It is possible that Prx VI
expression in human lung varies to some extent among
individuals given the fact that in Kinnula’s research PrxVI
showed immunoreactivity in alveolar type II cells only in
three of the four cases.
Despite the fact thatmany aspects of lung antioxidant
biology are currently well known, relationship between
di¡erent peroxide scavengers and contribution each of
peroxide scavengers to overall antioxidant activity are
still not clari¢ed completely.Usage of a model system in
PEROXIREDOXINVIINHUMANRESPIRATORYSYSTEM 151which antioxidant of activity of untreated epithelium ex-
tract is comparedwith antioxidant activity of epithelium
extract lacking in speci¢c enzymemay constitute one of
the possible approaches to the above problem.We ap-
plied a similar approach to our research. Di¡erence in
ability of untreated extract and of extract depleted by
Prx VI to prevent the inactivation of glutamine synthe-
tase by Fe3+/DTT/O2comes to about 70%, which enables
to suppose that Prx VI plays a leading role in scavenging
AOS by tissues.Despite the fact that the operation was
conducted in the presence of nonphysiological Prx acti-
vator (since physiological activator is not yet identi¢ed),
this experiment allows to evaluate to certain extent a
great Prx VI contribution to total antioxidant activity of
human airways.This high activity of Prx VI is consistent
to its localization at the epithelium surface of all respira-
tory airways from trachea to bronchioles implying that
Prx VI probably constitutes a powerful antioxidant of
¢rst line of defense.
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